Bosentan. Pulmonary hypertension: An option before eroprostenol infusion

Prescrire International

Volumn 14, Issue 76, 2005, Pages 47-50

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; CYCLOSPORIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; OXYGEN; PLACEBO; PROSTACYCLIN; ANTIINFECTIVE AGENT; NEW DRUG; SULFONAMIDE;

ANEMIA; ARTERY MALFORMATION; ARTICLE; CENTRAL VENOUS CATHETER; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; CRANIOFACIAL MALFORMATION; DAILY LIFE ACTIVITY; DEATH; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INHIBITION; DRUG MARKETING; DRUG METABOLISM; DYSPEPSIA; ENZYME INDUCTION; EUROPE; EXERCISE; FATIGUE; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HOT FLUSH; HUMAN; HYPOTENSION; INFUSION PUMP; LEG EDEMA; LIVER DYSFUNCTION; LONG TERM CARE; LUNG ARTERY PRESSURE; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; META ANALYSIS; NONHUMAN; OXYGEN THERAPY; PATIENT MONITORING; PHARYNGITIS; PRURITUS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REST; SCLERODERMA; SURVIVAL; SYMPTOM; TERATOGENICITY; TREATMENT OUTCOME; WALKING; COMPARATIVE STUDY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; DIURETICS; DRUGS, INVESTIGATIONAL; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; SULFONAMIDES;

EID: 17144428537     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. o - bosentan" 22 August 2003: 82 pages.
2. US Food and Drug Administration - Center for Drug Evaluation and Research "NDA - 21 290 bosentan Medical review of efficacy" 29 June 2001: 75 pages.
3. Channick RN et al. "Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study" Lancet 2001; 358: 1119-1123.
4. Badesch DB et al. "Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension" Current Ther Res 2002; 63 (4): 227-246.
5. Rubin LJ et al. "Bosentan therapy for pulmonary arterial hypertension" N Engl J Med 2002; 346 (12): 896-903 + erratum: 1258.
6. Sitbon O et al. "Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension" Chest 2003; 124 (1): 247-254.
7. Humbert M et al. "Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2" Eur Respir J 2004; 24 (3): 353-359.
8. US Food and Drug Administration - Center for Drug Evaluation and Research "NDA 21-290/5-001 bosentan medical review" 6 February 2003: 32 pages.
9. US Food and Drug Administration - Center for Drug Evaluation and Research "NDA 21 290 bosentan medical safety review" 6 July 2001: 74 pages.
10. Giaid A et al. "Expression of endothelin-1 in the lungs of patients with pulmonary hypertension" N Engl J Med 1993; 328 (24): 1732-1739.
11. MacLean MR "Endothelin-1: a mediator of pulmonary hypertension?" Pulm Pharmacol Ther 1998; 11: 125-132.
12. Galié N et al. "Relation of endothelin-I to survival in patients with primary pulmonary hypertension" Eur J Clin Invest 1996; 26 (suppl. 1): A48 (abstr. 273).